{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T18:08:36Z","timestamp":1760551716512,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017346","name":"Boehringer Ingelheim Japan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017346","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-cardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jjcc.2022.04.007","type":"journal-article","created":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T00:54:03Z","timestamp":1655340843000},"page":"255-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2"],"prefix":"10.1016","volume":"80","author":[{"given":"Takeshi","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Atarashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukihiro","family":"Koretsune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Yasaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Wakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taku","family":"Fukaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"author":"Boehringer Ingelheim","key":"10.1016\/j.jjcc.2022.04.007_bb0005"},{"author":"Bayer","key":"10.1016\/j.jjcc.2022.04.007_bb0010"},{"author":"Bristol-Myers Squibb, Pfizer Inc","key":"10.1016\/j.jjcc.2022.04.007_bb0015"},{"author":"Daiichi Sankyo","key":"10.1016\/j.jjcc.2022.04.007_bb0020"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0025","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1161\/CIRCULATIONAHA.110.004424","article-title":"Dabigatran etexilate","volume":"123","author":"Hankey","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0035","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.jjcc.2018.12.013","article-title":"Effectiveness and safety of long-term dabigatran among patients with non-valvular atrial fibrillation in clinical practice: J-Dabigatran Surveillance","volume":"73","author":"Inoue","year":"2019","journal-title":"J Cardiol"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0040","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s40119-020-00165-8","article-title":"Idarucizumab for emergency reversal of anticoagulant effects of dabigatran: interim results of a Japanese post-marketing surveillance study","volume":"9","author":"Yasaka","year":"2020","journal-title":"Cardiol Ther"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0045","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2012-11-468207","article-title":"A specific antidote for dabigatran: functional and structural characterization","volume":"121","author":"Schiele","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0050","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1056\/NEJMoa1707278","article-title":"Idarucizumab for dabigatran reversal - full cohort analysis","volume":"377","author":"Pollack","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0055","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0060","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s40264-018-0668-9","article-title":"Non-bleeding adverse events with the use of direct oral anticoagulants: a sequence symmetry analysis","volume":"41","author":"Maura","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0065","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1159\/000507046","article-title":"Adverse drug reactions during real-life use of direct oral anticoagulants in Italy: an update based on data from the Italian National Pharmacovigilance Network","volume":"10","author":"Lavalle","year":"2020","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0070","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.684638","article-title":"Direct oral anticoagulants: from randomized clinical trials to real-world clinical practice","volume":"12","author":"Roberti","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0075","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1161\/CIR.0000000000000665","volume":"140","author":"January","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0080","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1701005","article-title":"Uninterrupted dabigatran versus warfarin for ablation in atrial fibrillation","volume":"376","author":"Calkins","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0085","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/joa3.12491","article-title":"JCS\/JHRS 2019 guideline on non-pharmacotherapy of cardiac arrhythmias","volume":"37","author":"Nogami","year":"2021","journal-title":"J Arrhythm"},{"key":"10.1016\/j.jjcc.2022.04.007_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104717","article-title":"Dabigatran for Japanese patients with atrial fibrillation and prior stroke: a subgroup analysis of the J-Dabigatran Surveillance program","volume":"29","author":"Yasaka","year":"2020","journal-title":"J Stroke Cerebrovasc Dis"}],"container-title":["Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S091450872200096X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S091450872200096X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:07:46Z","timestamp":1760274466000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S091450872200096X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S091450872200096X"],"URL":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.04.007","relation":{},"ISSN":["0914-5087"],"issn-type":[{"type":"print","value":"0914-5087"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment strategy of dabigatran etexilate following the availability of idarucizumab in Japanese patients with non-valvular atrial fibrillation: J-Dabigatran Surveillance 2","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jjcc.2022.04.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}